The surgical and clinicopathological characteristics of primary mucinous ovarian cancer: a single institution 30-year retrospective analysis

被引：0

作者：

Aytekin, Okan ^{[1
]}

Yuksel, Dilek ^{[2
]}

Oktar, Okan ^{[2
]}

Cakir, Caner ^{[2
]}

Comert, Guensu Kimyon ^{[2
]}

Korkmaz, Vakkas ^{[2
]}

Engin-Ustun, Yaprak ^{[3
]}

Turan, Taner ^{[2
]}

机构：

[1] Univ Hlth Sci Turkey, Ankara City Hosp, Clin Gynecol Oncol, Ankara, Turkiye

[2] Univ Hlth Sci Turkey, Ankara Etlik Zubeyde Hanim Womens Hlth Training &, Clin Gynecol Oncol, Ankara, Turkiye

[3] Univ Hlth Sci Turkey, Ankara Etlik Zubeyde Hanim Womens Hlth & Res Ctr, Clin Obstet & Gynecol, Ankara, Turkiye

来源：

JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION | 2023年 / 24卷 / 04期

关键词：

Mucinous ovarian carcinoma; platinum-based chemotherapy; stage; survival; treatment response; ADVANCED-STAGE; SURVIVAL; CARCINOMA; CHEMOTHERAPY; RARE;

D O I：

10.4274/jtgga.galenos.2023.2022-8-1

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To evaluate the clinicopathological characteristics of primary mucinous ovarian carcinoma (MOC) and define oncologic outcomes. Material and Methods: This retrospective study reviewed patients diagnosed with primary MOC at a single institution and underwent primary treatment between 1990 and 2019. The clinicopathological factors affecting oncological outcomes and treatment response were evaluated. The Kaplan-Meier method was used to evaluate survival outcomes. Survival curves were compared using the log-rank test. Results: The cohort's (n=92) median (range) age was 48 (15-82) years. Seventy-five (81.5%) patients were in the International Federation of Gynecology and Obstetrics stage I-II. Forty patients received platinum-based adjuvant chemotherapy. The 5-year progression-free survival was 98% in stage I-II and 17% for stage III-IV (p<0.001). In multivariate analysis, the only independent risk factor for disease failure was stage (hazard ratio: 6.838, 95% confidence interval: 1,358-34,415; p=0.020). Conclusion: Advanced stage was an independent poor prognostic factor for recurrence in patient with MOC.

引用

页码：252 / 260

页数：9

共 27 条

[1] NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 [J].

Armstrong, Deborah K. ;

Alvarez, Ronald D. ;

Bakkum-Gamez, Jamie N. ;

Barroilhet, Lisa ;

Behbakht, Kian ;

Berchuck, Andrew ;

Berek, Jonathan S. ;

Chen, Lee-may ;

Cristea, Mihaela ;

DeRosa, Marie ;

ElNaggar, Adam C. ;

Gershenson, David M. ;

Gray, Heidi J. ;

Hakam, Ardeshir ;

Jain, Angela ;

Leath, Charles A., III ;

Liu, Joyce ;

Mahdi, Haider ;

Matei, Daniela ;

McHale, Michael ;

McLean, Karen ;

O'Malley, David M. ;

Penson, Richard T. ;

Percac-Lima, Sanja ;

Ratner, Elena ;

Remmenga, Steven W. ;

Sabbatini, Paul ;

Werner, Theresa L. ;

Zsiros, Emese ;

Burns, Jennifer L. ;

Engh, Anita M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (08) :896-+

[2] Comparison of stage III mucinous and serous ovarian cancer: a case-control study [J].

Cuylan, Zeliha Firat ;

Karabuk, Emine ;

Oz, Murat ;

Turan, Ahmet Taner ;

Meydanli, Mehmet M. ;

Taskin, Salih ;

Sari, Mustafa Erkan ;

Sahin, Hanifi ;

Ulukent, Suat C. ;

Akbayir, Ozgur ;

Gungorduk, Kemal ;

Gungor, Tayfun ;

Kose, Mehmet F. ;

Ayhan, Ali .

JOURNAL OF OVARIAN RESEARCH, 2018, 11

[3] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].

du Bois, Andreas ;

Reuss, Alexander ;

Pujade-Lauraine, Eric ;

Harter, Philipp ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

CANCER, 2009, 115 (06) :1234-1244

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer [J].

Eisenhauer, Eric L. ;

Abu-Rustum, Nadeem R. ;

Sonoda, Yukio ;

Aghajanian, Carol ;

Barakat, Richard R. ;

Chi, Dennis S. .

GYNECOLOGIC ONCOLOGY, 2008, 108 (02) :276-281

[6] An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor [J].

Gore, Martin ;

Hackshaw, Allan ;

Brady, William E. ;

Penson, Richard T. ;

Zaino, Richard ;

McCluggage, W. Glenn ;

Ganesan, Raji ;

Wilkinson, Nafisa ;

Perren, Timothy ;

Montes, Ana ;

Summers, Jeffrey ;

Lord, Rosemary ;

Dark, Graham ;

Rustin, Gordon ;

Mackean, Melanie ;

Reed, Nicholas ;

Kehoe, Sean ;

Frumovitz, Michael ;

Christensen, Helen ;

Feeney, Amanda ;

Ledermann, Jonathan ;

Gershenson, David M. .

GYNECOLOGIC ONCOLOGY, 2019, 153 (03) :541-548

[7] Mucinous Ovarian Carcinoma [J].

Hackshaw, Allan ;

Gershenson, David ;

Ledermann, Jonathan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01)

[8] Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment [J].

Hess, V ;

A'Hern, R ;

Nasiri, N ;

King, DM ;

Blake, PR ;

Barton, DPJ ;

Shepherd, JH ;

Ind, T ;

Bridges, J ;

Harrington, K ;

Kaye, SB ;

Gore, ME .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1040-1044

[9] Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma [J].

Hollis, Robert L. ;

Stillie, Lorna J. ;

Hopkins, Samantha ;

Bartos, Clare ;

Churchman, Michael ;

Rye, Tzyvia ;

Nussey, Fiona ;

Fegan, Scott ;

Nirsimloo, Rachel ;

Inman, Gareth J. ;

Herrington, C. Simon ;

Gourley, Charlie .

CANCERS, 2021, 13 (22)

[10] Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study [J].

Karabuk, Emine ;

Kose, M. Faruk ;

Hizli, Deniz ;

Taskin, Salih ;

Karadag, Burak ;

Turan, Taner ;

Boran, Nurettin ;

Ozfuttu, Ahmet ;

Ortac, U. Firat .

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) :160-166

← 1 2 3 →